EASTWOOD BIO-MEDICAL CANADA (EBM.CA) Fundamental Analysis & Valuation

TSX-V:EBM • CA27783W1059

0.55 CAD
0 (0%)
Last: Mar 13, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This EBM.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

1

EBM gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 13 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of EBM have multiple concerns. EBM has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

2

1. EBM.CA Profitability Analysis

1.1 Basic Checks

  • In the past year EBM has reported negative net income.
  • EBM had a positive operating cash flow in the past year.
  • In the past 5 years EBM always reported negative net income.
  • EBM had a negative operating cash flow in each of the past 5 years.
EBM.CA Yearly Net Income VS EBIT VS OCF VS FCFEBM.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200K -400K -600K -800K

1.2 Ratios

  • EBM's Return On Assets of -189.94% is on the low side compared to the rest of the industry. EBM is outperformed by 84.62% of its industry peers.
Industry RankSector Rank
ROA -189.94%
ROE N/A
ROIC N/A
ROA(3y)-101.2%
ROA(5y)-96.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EBM.CA Yearly ROA, ROE, ROICEBM.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400

1.3 Margins

  • EBM has a Gross Margin of 63.91%. This is amongst the best in the industry. EBM outperforms 92.31% of its industry peers.
  • EBM's Gross Margin has improved in the last couple of years.
  • The Profit Margin and Operating Margin are not available for EBM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.91%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y11.47%
GM growth 5Y8.17%
EBM.CA Yearly Profit, Operating, Gross MarginsEBM.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. EBM.CA Health Analysis

2.1 Basic Checks

  • EBM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • EBM has about the same amout of shares outstanding than it did 1 year ago.
  • EBM has about the same amout of shares outstanding than it did 5 years ago.
  • EBM has a worse debt/assets ratio than last year.
EBM.CA Yearly Shares OutstandingEBM.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
EBM.CA Yearly Total Debt VS Total AssetsEBM.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M

2.2 Solvency

  • EBM has an Altman-Z score of -40.11. This is a bad value and indicates that EBM is not financially healthy and even has some risk of bankruptcy.
  • EBM has a Altman-Z score of -40.11. This is amonst the worse of the industry: EBM underperforms 84.62% of its industry peers.
  • The Debt to FCF ratio of EBM is 3.38, which is a good value as it means it would take EBM, 3.38 years of fcf income to pay off all of its debts.
  • EBM has a Debt to FCF ratio of 3.38. This is amongst the best in the industry. EBM outperforms 84.62% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 3.38
Altman-Z -40.11
ROIC/WACCN/A
WACC8.03%
EBM.CA Yearly LT Debt VS Equity VS FCFEBM.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1M -1M 2M 3M

2.3 Liquidity

  • A Current Ratio of 0.02 indicates that EBM may have some problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 0.02, EBM is doing worse than 84.62% of the companies in the same industry.
  • EBM has a Quick Ratio of 0.02. This is a bad value and indicates that EBM is not financially healthy enough and could expect problems in meeting its short term obligations.
  • The Quick ratio of EBM (0.02) is worse than 84.62% of its industry peers.
Industry RankSector Rank
Current Ratio 0.02
Quick Ratio 0.02
EBM.CA Yearly Current Assets VS Current LiabilitesEBM.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. EBM.CA Growth Analysis

3.1 Past

  • EBM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.49%, which is quite good.
  • The Revenue has decreased by -9.03% in the past year.
  • The Revenue for EBM have been decreasing by -11.50% on average. This is quite bad
EPS 1Y (TTM)15.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.94%
Revenue 1Y (TTM)-9.03%
Revenue growth 3Y-10.55%
Revenue growth 5Y-11.5%
Sales Q2Q%-33.35%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EBM.CA Yearly Revenue VS EstimatesEBM.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200K 400K 600K 800K 1M

More info and screens

Find the best growth stocksShow best growing peers

1

4. EBM.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for EBM. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EBM.CA Price Earnings VS Forward Price EarningsEBM.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

  • EBM's Price/Free Cash Flow is on the same level as the industry average.
Industry RankSector Rank
P/FCF 1795.71
EV/EBITDA N/A
EBM.CA Per share dataEBM.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.01 -0.02

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. EBM.CA Dividend Analysis

5.1 Amount

  • EBM does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

EBM.CA Fundamentals: All Metrics, Ratios and Statistics

EASTWOOD BIO-MEDICAL CANADA

TSX-V:EBM (3/13/2026, 7:00:00 PM)

0.55

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)09-29
Earnings (Next)N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners0.2%
Ins Owner ChangeN/A
Market Cap37.89M
Revenue(TTM)594.60K
Net Income(TTM)-411.80K
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 63.72
P/FCF 1795.71
P/OCF 1795.71
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.01
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0
FCFY0.06%
OCF(TTM)0
OCFY0.06%
SpS0.01
BVpS-0.02
TBVpS-0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -189.94%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.91%
FCFM 3.55%
ROA(3y)-101.2%
ROA(5y)-96.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y11.47%
GM growth 5Y8.17%
F-Score5
Asset Turnover2.74
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 3.38
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.02
Quick Ratio 0.02
Altman-Z -40.11
F-Score5
WACC8.03%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)15.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.94%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-9.03%
Revenue growth 3Y-10.55%
Revenue growth 5Y-11.5%
Sales Q2Q%-33.35%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y20.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y162.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y168.51%
OCF growth 3YN/A
OCF growth 5YN/A

EASTWOOD BIO-MEDICAL CANADA / EBM.CA FAQ

What is the ChartMill fundamental rating of EASTWOOD BIO-MEDICAL CANADA (EBM.CA) stock?

ChartMill assigns a fundamental rating of 1 / 10 to EBM.CA.


What is the valuation status of EASTWOOD BIO-MEDICAL CANADA (EBM.CA) stock?

ChartMill assigns a valuation rating of 1 / 10 to EASTWOOD BIO-MEDICAL CANADA (EBM.CA). This can be considered as Overvalued.


Can you provide the profitability details for EASTWOOD BIO-MEDICAL CANADA?

EASTWOOD BIO-MEDICAL CANADA (EBM.CA) has a profitability rating of 2 / 10.